ANDA 215886, held by Mankind Pharma. Ofloxacin.
As of Nov 16, 2026, ANDA 215886 (Ofloxacin), held by Mankind Pharma, was first approved by FDA on Nov 23, 2022, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: *Efficacy for this organism was studied in fewer than 10 infections CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Enterobacter cloacae Staphylococcus epidermidis Haemophilus influenzae Streptococcus pneumoniae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Pseudomonas aeruginosa Staphylococcus epidermidis Serratia marcescens* Streptococcus pneumoniae Anaerobic species: Propionibacterium acnes
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 23, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ofloxacin0.3% · solution/drops;ophthalmic | Ofloxacin | Rx |
| Aug 25, 2023 | Supplement 2Manufacturing | Approved | None posted |
| Nov 23, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters